Epicept Corporation to Present at the NYSSA 12th Annual Biotech and Specialty Pharma Conference

Epicept Corporation to Present at the NYSSA 12th Annual Biotech and Specialty
Pharma Conference 

TARRYTOWN, N.Y.--(BUSINESS WIRE)-- Regulatory News: 

EpiCept Corporation (NASDAQ and OMX Nordic Exchange: EPCT) today announced that
Robert W. Cook, Senior Vice President and CFO, will be presenting at the New
York Society of Security Analysts (NYSSA) 12th Annual Biotech & Specialty Pharma
Conference on December 2, 2008 at 1177 Avenue of the Americas, 2nd Floor in New
York, NY. Mr. Cook will present a company overview from 10:20 - 10:55 a.m. local
time. 

The presentation will be available live via webcast on December 2, 2008 and for
90 days thereafter. The webcast can be accessed by visiting www.epicept.com. 

About EpiCept Corporation 

EpiCept is focused on unmet needs in the treatment of cancer and pain. The
Company's broad portfolio of pharmaceutical product candidates includes Ceplene,
a cytokine immunomodulator that recently received final marketing approval from
the EMEA for the remission maintenance of AML patients and several pain
therapies in clinical development. In addition, EpiCept's ASAP technology, a
proprietary live cell high-throughput caspase-3 screening technology, can
efficiently identify new cancer drug candidates and molecular targets that
selectively induce apoptosis in cancer cells. Two oncology drug candidates
currently in clinical development that were discovered using this technology
have also been shown to act as vascular disruption agents in a variety of solid
tumors. 

Forward-Looking Statements 

This news release and any oral statements made with respect to the information
contained in this news release, contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include statements which express plans, anticipation,
intent, contingency, goals, targets, future development and are otherwise not
statements of historical fact. These statements are based on EpiCept's current
expectations and are subject to risks and uncertainties that could cause actual
results or developments to be materially different from historical results or
from any future results expressed or implied by such forward-looking statements.
Factors that may cause actual results or developments to differ materially
include: the risk that Ceplene® will not be launched in Europe in the first
quarter of 2009 or achieve significant commercial success, the risk that we are
unable to find a suitable marketing partner for Ceplene® on attractive terms, a
timely basis or at all, the risk that any required post-approval clinical study
will not be successful, the risk that EpiCept will not be able to maintain its
final regulatory approval or marketing authorization, the risks associated with
the adequacy of our existing cash resources, our need to raise additional
financing to continue to meet our capital needs and our ability to continue as a
going concern, the risks associated with our ability to continue to meet our
obligations under our existing debt agreements or that we may default on our
loans or that our lenders may declare the Company in default, the risk that the
Company's securities may be delisted by The Nasdaq Capital Market or the OMX
Nordic Exchange, the risk that Myriad's development of Azixa™ will not be
successful, the risk that Azixa™ will not receive regulatory approval or achieve
significant commercial success, the risk that we will not receive any
significant payments under our agreement with Myriad, the risk that the
development of our other apoptosis product candidates will not be successful,
the risk that our ASAP technology will not yield any successful product
candidates, the risk that clinical trials for NP-1, including our current
clinical trial in PHN, or EPC2407 will not be successful, the risk that NP-1 or
EPC2407 will not receive regulatory approval or achieve significant commercial
success, the risk that our other product candidates that appeared promising in
early research and clinical trials do not demonstrate safety and/or efficacy in
larger-scale or later stage clinical trials, the risks associated with our
dependence upon key personnel, the risks associated with reliance on
collaborative partners and others for further clinical trials, development,
manufacturing and commercialization of our product candidates; the cost, delays
and uncertainties associated with our scientific research, product development,
clinical trials and regulatory approval process; our history of operating losses
since our inception; the highly competitive nature of our business; risks
associated with litigation; and risks associated with our ability to protect our
intellectual property. These factors and other material risks are more fully
discussed in EpiCept's periodic reports, including its reports on Forms 8-K,
10-Q and 10-K and other filings with the U.S. Securities and Exchange
Commission. You are urged to carefully review and consider the disclosures found
in EpiCept's filings, which are available at www.sec.gov or at www.epicept.com.
You are cautioned not to place undue reliance on any forward-looking statements,
any of which could turn out to be wrong due to inaccurate assumptions, unknown
risks or uncertainties or other risk factors. 

EPCT-GEN 

*Azixa is a registered trademark of Myriad Genetics, Inc. 


Contacts
EpiCept Corporation:
Robert W. Cook, 914-606-3500
rcook@epicept.com
or
Media:
Feinstein Kean Healthcare
Greg Kelley, 617-577-8110
gregory.kelley@fkhealth.com
or
Investors:
Lippert/Heilshorn & Associates
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com